Lilly’s Mounjaro Fails to Win EU Heart-Failure Label Extension

Eli Lilly & Co. failed to win backing from the European Union’s medicines regulator for the use of its weight-loss drug Mounjaro to treat a certain kind of heart failure in adults with obesity.

The European Medicine Agency’s drug advisory panel said Friday it remains uncertain whether the reduction in heart-failure hospitalizations in a trial reflects a weight-loss-independent effect of Mounjaro.